Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal investigation.

The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.

A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus. Recap of the Week’s ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...

Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corporation (SCHW), ...

Morgan Stanley's optimistic outlook for Gilead Sciences' HIV prevention medication Lenacapavir has positioned the company for ...

Three bovine veterinarians had undetected H5N1 avian influenza infections despite no apparent contact with infected cows, ...